To avoid common gene therapy manufacturing delays, Ray Therapeutics invested heavily in its Chemistry, Manufacturing, and Controls (CMC) process early. They established a commercial-scale process *before* dosing a single patient, eliminating the risky and time-consuming transition from clinical to commercial material.
CEO Paul Bresge's entry into biotech was directly triggered by his 15-year-old daughter being diagnosed with a blinding disease and told there was no hope. This personal stake deeply informs the company's patient-first culture and strategic direction, moving beyond a purely commercial motivation.
Early optogenetics required light-enhancing goggles, creating a complex regulatory and commercial path for a combined therapeutic and device. Ray Therapeutics' therapy uses a protein sensitive enough for natural light, avoiding the 'heavier lift' of a combination product and simplifying the path to market.
Standard retina clinics lack expertise in testing blind patients. Ray Therapeutics proactively built its own Vision Research and Assessment Institute two years before its trial to run natural history studies with low-vision experts. This allowed them to define appropriate endpoints and reduce data variability.
After 10 years at his first company (J-Site) developing a therapy to slow disease, CEO Paul Bresge saw his daughter's condition advance. He founded Ray Therapeutics to target late-stage patients who had already lost photoreceptors, a more urgent and underserved population.
To make its patient-centric mission authentic, Ray Therapeutics organizes sessions for all employees, including technical staff in manufacturing (CMC), to meet and hear from patients. This initiative, sparked by an employee's request, bridges the gap between the conceptual 'patient' and a real person.